Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis of gastrointestinal stromal tumors. Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors. METHODS: We conducted an open-label, randomized, multicenter trial to evaluate the activity of imatinib in patients with advanced gastrointestinal stromal tumor. We assessed antitumor response and the safety and tolerability of the drug. Pharmacokinetics were assessed in a subgroup of patients. RESULTS: A total of 147 patients were randomly assigned to receive 400 mg or 600 mg of imatinib daily. Overall, 79 patients (53.7 percent) had a partial response, 41 patients (27.9 percent) had stable disease, and for technical reasons, response could not be evaluated in 7 patients (4.8 percent). No patient had a complete response to the treatment. The median duration of response had not been reached after a median follow-up of 24 weeks after the onset of response. Early resistance to imatinib was noted in 20 patients (13.6 percent). Therapy was well tolerated, although mild-to-moderate edema, diarrhea, and fatigue were common. Gastrointestinal or intraabdominal hemorrhage occurred in approximately 5 percent of patients. There were no significant differences in toxic effects or response between the two doses. Imatinib was well absorbed, with pharmacokinetics similar to those reported in patients with chronic myeloid leukemia. CONCLUSIONS: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor. Inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinal stromal tumors, which resist conventional chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationDiagnosis of gastrointestinal stromal tumors: A consensus approach
Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Self-citationDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationTwo Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival
DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., & Brennan, M. F. (2000) · Annals of Surgery · doi:10.1097/00000658-200001000-00008 · Cited by 2,554
Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441404 · Cited by 2,037
Self-citationBuchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Self-citationvan Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Self-citationHeinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., & Zigler, A. J. (2000) · Blood · doi:10.1182/blood.v96.3.925 · Cited by 1,071
Self-citation
Research works printed but not linked: 4
- Rubin BP, 2001, Cancer Res, 61, 8118
- Goss GA, 2000, Prog Proc Am Soc Clin Oncol, 19, 599a
- Buchdunger E, 2000, J Pharmacol Exp Ther, 295, 139
- Peng B, 2001, Prog Proc Am Soc Clin Oncol, 20, 71a
Cited by
Items 701–800 of 1,007
Pediatric gastrointestinal stromal tumors and leiomyosarcoma
Cypriano, M. S., Jenkins, J. J., Pappo, A. S., Rao, B. N., & Daw, N. C. (2004) · Cancer · doi:10.1002/cncr.20352 · Cited by 77
Protein kinase C-θ regulates KIT expression and proliferation in gastrointestinal stromal tumors
Ou, W.-B., Zhu, M.-J., Demetri, G. D., Fletcher, C. D. �., & Fletcher, J. A. (2008) · Oncogene · doi:10.1038/onc.2008.177 · Cited by 82
Self-citationManagement and Outcome of Gastrointestinal Stromal Tumors of the Duodenum
Chung, J. C., Chu, C. W., Cho, G. S., Shin, E. J., Lim, C. W., Kım, H. C., & Song, O. P. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1170-6 · Cited by 77
Gastrointestinal Stromal Tumors
Ó’Riain, C., Corless, C. L., Heinrich, M. C., Keegan, D., Vioreanu, M. H., Maguire, D., & Sheahan, K. D. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000173024.79852.08 · Cited by 77
Self-citationKretz, O., Weiss, H., Schumacher, M. M., & Groß, G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02117.x · Cited by 80
Gebreyohannes, Y. K., Woźniak, A., Zhai, M.-E., Wellens, J., Cornillie, J., Vanleeuw, U., Evans, E. K., Gardino, A. K., Lengauer, C., Dêbiec‐Rychter, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1858 · Cited by 80
Angelini, S., Pantaleo, M. A., Ravegnini, G., Zenesini, C., Cavrini, G., Nannini, M., Fumagalli, E. R., Palassini, E., Saponara, M., Battista, M. D., et al. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.015 · Cited by 76
Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors
Xia, L., Zhang, M., Lin, J., Li, X., & Wu, X. (2010) · Surgery Today · doi:10.1007/s00595-009-4171-x · Cited by 76
Protein Kinases as Targets for Cancer Treatment
Giamas, G., Stebbing, J., Vorgias, C. E., & Knippschild, U. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1005 · Cited by 86
Kozu, Y., Tsuta, K., Kohno, T., Sekine, I., Yoshida, A., WATANABE, S.-I. I., Tamura, T., Yokota, J., Suzuki, K., Asamura, H., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.11.003 · Cited by 81
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma
Bailey, H. H., Mahoney, M. R., Ettinger, D. S., Maples, W. J., Fracasso, P. M., Traynor, A. M., Erlichman, C., & Okuno, S. H. (2006) · Cancer · doi:10.1002/cncr.22308 · Cited by 75
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
Lassus, H. J., Sihto, H. J., Leminen, A., Nordling, S., Joensuu, H., Nupponen, N. N., & Bützow, R. C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602252 · Cited by 75
Self-citationc‐kit gene mutations in intracranial germinomas
Sakuma, Y., Sakurai, S., Oguni, S., Satoh, M., Hironaka, M., & Saito, K. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03251.x · Cited by 75
MET Receptor Tyrosine Kinase Sequence Alterations in Differentiated Thyroid Carcinoma
Wasenius, V.-M., Hemmer, S., Karjalainen‐Lindsberg, M., Nupponen, N. N., Franssila, K., & Joensuu, H. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000156103.37756.e2 · Cited by 75
Self-citationThe FIP1L1-PDGFR?? kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia
Cools, J., Stover, E. H., Włodarska, I., Marynen, P., & Gilliland, D. G. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200401000-00008 · Cited by 75
Booth, C. M., Calvert, H., Giaccone, G., Lobbezoo, M. W., Eisenhauer, E. A., & Seymour, L. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.031 · Cited by 75
Penzel, R., Aulmann, S., Moock, M., Schwarzbach, M., Rieker, R. J., & Mechtersheimer, G. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.021766 · Cited by 75
Glucose addiction in cancer therapy: advances and drawbacks
Granja, S., Pinheiro, C. M., Reis, R. M., Martinho, O., & Baltazar, F. (2015) · Current Drug Metabolism · doi:10.2174/1389200216666150602145145 · Cited by 80
Pulmonary adenocarcinoma: A renewed entity in 2011
Kadara, H. N., Kabbout, M., & Wistuba, I. I. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.02095.x · Cited by 85
Implications of Pharmacogenomics for Drug Development and Clinical Practice
Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S., & Schulman, K. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.20.2331 · Cited by 76
van Steensel, L., Paridaens, D. A., Schrijver, B., Dingjan, G. M., van Daele, P. L. A., van Hagen, P. M., van den Bosch, W. A., Drexhage, H. A., Hooijkaas, H., & Dik, W. A. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2443 · Cited by 76
Matei, D. E., Emerson, R. E., Schilder, J. M., Menning, N., Baldridge, L. A., Johnson, C. S., Breen, T., McClean, J., Stephens, D., Whalen, C., et al. (2008) · Cancer · doi:10.1002/cncr.23605 · Cited by 80
Wilczynski, S. P., Chen, Y. Y., Chen, W., Howell, S. B., Shively, J. E., & Alberts, D. S. (2005) · Human Pathology · doi:10.1016/j.humpath.2004.11.009 · Cited by 74
Sym, S. J., Ryu, M., Lee, J., Chang, H. M., Kim, T., Kim, H. C., Kim, K. H., Yook, J. H., Kim, B. S., & Kang, Y. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21065 · Cited by 75
Jose, A., Ninave, K. M., Karnam, S., & Venuganti, V. V. K. (2018) · Journal of Liposome Research · doi:10.1080/08982104.2018.1502315 · Cited by 75
FLT3 Tyrosine Kinase Inhibitors
Levis, M. J., & Small, D. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05079 · Cited by 78
Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum
Winfield, R. D., Hochwald, S. N., Vogel, S. B., Hemming, A. W., Liu, C., Cance, W. G., & Grobmyer, S. R. (2006) · The American Surgeon · doi:10.1177/000313480607200811 · Cited by 73
FoxO tumor suppressors and BCR–ABL-induced leukemia: A matter of evasion of apoptosis
Jagani, Z., Singh, A. J., & Khosravi‐Far, R. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.003 · Cited by 84
Bechtold, R. E., Chen, M. Y. M., Stanton, C. A., Savage, P. D., & Levine, E. A. (2003) · Abdominal Imaging · doi:10.1007/s00261-003-0021-2 · Cited by 73
Tang, X., Kadara, H. N., Behrens, C., Liu, D. D., Xiao, Y., Rice, D. C., Gazdar, A. F., Fujimoto, J., Moran, C. A., Varella‐Garcia, M., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1412 · Cited by 77
Implications of PET based molecular imaging on the current and future practice of medicine
Alavi, A. A., Kung, J. W., & Zhuang, H. (2004) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2003.09.007 · Cited by 74
Targeted Inhibition of Multiple Receptor Tyrosine Kinases in Mesothelioma
Ou, W., Hubert, C. G., Fletcher, J. A., Corson, J. M., Bueno, R., Flynn, D. L., & Sugarbaker, D. J. (2011) · Neoplasia · doi:10.1593/neo.101156 · Cited by 77
Self-citationRossi, G., Valli, R., Bertolini, F., Marchioni, A., Cavazza, A., Mucciarini, C., Migaldi, M., Federico, M., Trentini, G. P., & Sgambato, A. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02128.x · Cited by 72
Plexiform angiomyxoid myofibroblastic tumor of the stomach
Takahashi, Y. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i23.2835 · Cited by 72
Rethinking clinical trials for cytostatic drugs
Millar, A. W., & Lynch, K. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1124 · Cited by 72
Paniagua, R. T., Chang, A., Mariano, M. M., Stein, E. A., Wang, Q., Lindstrom, T. M., Sharpe, O., Roscow, C., Ho, P. P., Lee, D. M., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2940 · Cited by 73
Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss
François, H., Coppo, P., Hayman, J.-P., Fouqueray, B. L., Mougenot, B., & Ronco, P. M. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.039 · Cited by 76
Giorgi, U. D., Aliberti, C., Benea, G., Conti, M., & Marangolo, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2046 · Cited by 72
Mano, M. S., Rosa, D. D., de Azambuja, E., Ismael, G., & Durbecq, V. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.10.001 · Cited by 76
Corbacioglu, S., Kılıç, M., Westhoff, M., Reinhardt, D., Fulda, S., & Debatin, K. (2006) · Blood · doi:10.1182/blood-2006-05-021691 · Cited by 78
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
Woll, P. J. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1526 · Cited by 78
Merkel Cell Carcinoma: Chemotherapy and Emerging New Therapeutic Options
Desch, L., & Kunstfeld, R. (2013) · Journal of Skin Cancer · doi:10.1155/2013/327150 · Cited by 71
Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor
Li, J., Gong, J., Wu, A., & Shen, L. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2011.01.005 · Cited by 71
Prenen, H., Guetens, G., Boeck, G. D., Dêbiec‐Rychter, M., Manley, P. W., Schöffski, P., van Oosterom, A. T., & de Bruijn, E. A. (2006) · Pharmacology · doi:10.1159/000091943 · Cited by 71
Meyer, M., Hohenberger, P., Apfaltrer, P., Henzler, T., Dinter, D. J., Schoenberg, S. O., & Fink, C. (2013) · European Journal of Radiology · doi:10.1016/j.ejrad.2013.01.006 · Cited by 71
Hemminger, J. A., & Iwenofu, O. H. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04150.x · Cited by 71
von Mehren, M., & Widmer, N. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.10.001 · Cited by 71
Tielen, R., Verhoef, C. K., van Coevorden, F., Gelderblom, H. A. J., Sleijfer, S., Hartgrink, H. H., Bonenkamp, J. J., van der Graaf, W. T. A., & de Wilt, J. H. W. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.09.004 · Cited by 71
Martinho, O., Oliveira, R. J. D. S., Miranda‐Gonçalves, V., Clara, C., Almeida, J. R., Carvalho, A. L., Barata, J. T., & Reis, R. M. (2013) · Translational Oncology · doi:10.1593/tlo.12400 · Cited by 76
Martín‐Broto, J., Gutierrez, A. M., Garcia-del-Muro, X., López‐Guerrero, J. A., Martínez‐Trufero, J., de Sande, L. M., Laínez, N., Maurel, J., Juan, A. D., Losa, F., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq047 · Cited by 73
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
Reilley, M. J., Bailey, A. M., Subbiah, V., Jankú, F., Naing, A., Falchook, G. S., Karp, D. D., Piha-Paul, S. A., Tsimberidou, A. M., Fu, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0238-1 · Cited by 77
Management of rectal gastrointestinal stromal tumor
Kameyama, H., Kanda, T., Tajima, Y., Shimada, Y., Ichikawa, H., Hanyu, T., Ishikawa, T., & Wakai, T. (2018) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2018.01.08 · Cited by 78
Targeting Pdgf Receptors in Cancer Rationales and Proof of Concept Clinical Trials
George, D. J. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_12 · Cited by 77
Kobayashi, K., Gupta, S. K., Trent, J. C., Vauthey, J., Krishnamurthy, S., Ensor, J., Ahrar, K., Wallace, M. J., Madoff, D. C., Murthy, R., et al. (2006) · Cancer · doi:10.1002/cncr.22336 · Cited by 73
Hassan, I., You, Y. N., Dozois, E. J., Shayyan, R., Smyrk, T. C., Okuno, S. H., & Donohue, J. H. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0503-8 · Cited by 71
Gastrointestinal Stromal Tumors (GISTs) on Prostate Needle Biopsy
Herawi, M., Montgomery, E. A., & Epstein, J. I. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000209847.59670.c8 · Cited by 71
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT
Bauer, S., Corless, C. L., Heinrich, M. C., Dirsch, O., Antoch, G., Kanja, J., Seeber, S., & Schütte, J. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0564-x · Cited by 71
Self-citationHirota, S., Tateishi, U., Nakamoto, Y., Yamamoto, H., Sakurai, S., Kikuchi, H., Kanda, T., Kurokawa, Y., Cho, H., Nishida, T., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02488-1 · Cited by 83
Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma
Armistead, P. M., Salganick, J. A., Roh, J. S., Steinert, D. M., PATEL, S. R., Munsell, M. F., El‐Naggar, A. K., Benjamin, R. S., Zhang, W., & Trent, J. C. (2007) · Cancer · doi:10.1002/cncr.23038 · Cited by 74
Choy, E., Hornicek, F. J., MacConaill, L. E., Harmon, D. C., Tariq, Z., Garraway, L. A., & Duan, Z. (2011) · Cancer · doi:10.1002/cncr.26617 · Cited by 73
Nakamura, K., Akagi, S., Ogawa, A., KUSANO, K. F., Matsubara, H., Miura, D., Fuke, S., Nishii, N., Nagase, S., Kohno, K., et al. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.02.024 · Cited by 70
Alberts, D. S., Liu, P. Y., Wilczynski, S. P., JANG, A., MOON, J., Ward, J. H., BECK, J. T., Clouser, M. C., & Markman, M. M. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00882.x · Cited by 70
Pantaleo, M. A., Astolfi, A., Battista, M. D., Heinrich, M. C., Paterini, P., Scotlandi, K., Santini, D., Catena, F., Manara, M. C., Nannini, M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24595 · Cited by 70
Self-citationScotlandi, K., Manara, M. C., Strammiello, R., Landuzzi, L., Benini, S., Perdichizzi, S., Serra, M., Astolfi, A., Nicoletti, G., Lollini, P., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.111 · Cited by 70
Arnedos, M., Soria, J., André, F., & Tursz, T. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.002 · Cited by 71
Gastrointestinal stromal tumors–a review
Joensuu, H., & Kindblom, L. (2004) · Acta Orthopaedica Scandinavica · doi:10.1080/00016470410001708340 · Cited by 70
Self-citationZhang, J. Q., Zeng, S., Vitiello, G. A., Seifert, A. M., Medina, B. D., Beckman, M. J., Loo, J. K., Santamaria-Barria, J., Maltbaek, J. H., Param, N. J., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0345 · Cited by 66
Mumprecht, S., Matter, M., Pavelic, V., & Ochsenbein, A. F. (2006) · Blood · doi:10.1182/blood-2006-04-018705 · Cited by 70
Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs)
Price, V. E., Zieleńska, M., Chilton‐MacNeill, S., Smith, C. S., & Pappo, A. S. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20377 · Cited by 70
Gastrointestinal stromal tumor: a review of current and emerging therapies
Al-Share, B. A., Alloghbi, A., Hallak, M. N. A., Uddin, M. H., Azmi, A. S., Mohammad, R. M., Kim, S. H., Shields, A. F., & Philip, P. A. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09961-7 · Cited by 75
Surgical management of rectal gastrointestinal stromal tumors
Tielen, R., Verhoef, C. K., van Coevorden, F., Reyners, A. K. L., van der Graaf, W. T. A., Bonenkamp, J. J., van Etten, B., & de Wilt, J. H. W. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23223 · Cited by 69
State-of-the Art Therapy for Gastrointestinal Stromal Tumors
Blanke, C. D., & Corless, C. L. (2005) · Cancer Investigation · doi:10.1081/cnv-200055972 · Cited by 69
Self-citationLessons learned from the development of imatinib
Lydon, N., & Druker, B. J. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.10.002 · Cited by 77
Self-citationSambol, E. B., Ambrosini, G., Geha, R. C., Kennealey, P. T., DeCarolis, P. L., O’Connor, R., Wu, Y. V., Motwani, M., Chen, J., Schwartz, G. K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2933 · Cited by 69
Self-citationLevy, A. D., Remotti, H. E., Thompson, W. M., Sobin, L. H., & Miettinen, M. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.180.6.1801607 · Cited by 69
The ethical use of mandatory research biopsies
Olson, E. M., Lin, N., Krop, I. E., & Winer, E. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.114 · Cited by 72
Shalauddin, M., Akhter, S., Bagheri, S., Karim, M. S. A., Kadri, N. A., & Basirun, W. J. (2017) · International Journal of Hydrogen Energy · doi:10.1016/j.ijhydene.2017.06.163 · Cited by 68
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970
Corbin, A. S., Griswold, I. J., La Rosée, P., Yee, K. W. H., Heinrich, M. C., Reimer, C. L., Druker, B. J., & Deininger, M. W. N. (2004) · Blood · doi:10.1182/blood-2004-06-2189 · Cited by 68
Self-citationGastrointestinal Stromal Tumors
Zalcberg, J. R., Yip, D., Hemmings, C. T., Mann, G. B., & Blanke, C. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-13306-0_6 · Cited by 68
Self-citationPerspective on updated treatment guidelines for patients with gastrointestinal stromal tumors
Blay, J., von Mehren, M., & Blackstein, M. E. (2010) · Cancer · doi:10.1002/cncr.25267 · Cited by 69
Reichardt, P., Demetri, G. D., Gelderblom, H. A. J., Rutkowski, P. L., Im, S., Gupta, S., Kang, Y., Schöffski, P., Schuette, J., Soulières, D., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2051-5 · Cited by 67
Self-citationSignaling of c‐kit in dendritic cells influences adaptive immunity
Ray, P., Krishnamoorthy, N., Oriss, T. B., & Ray, A. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05122.x · Cited by 77
Adjuvant treatment of GIST: patient selection and treatment strategies
Joensuu, H. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.74 · Cited by 74
Self-citationHo, W. L., Wong, H., & Yau, T. C. C. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2012.02518.x · Cited by 67
Janeway, K. A., Zhu, M. J., Barretina, J., Pérez‐Atayde, A. R., Demetri, G. D., & Fletcher, J. A. (2010) · International Journal of Cancer · doi:10.1002/ijc.25247 · Cited by 67
Self-citationTeng, J. F. T., Mabasa, V. H., & Ensom, M. H. H. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31823cdec9 · Cited by 71
Cassaday, R. D., Goy, A. H., Advani, S. H., CHAWLA, P. M., Nachankar, R., Gandhi, M., & Gopal, A. K. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.021 · Cited by 69
DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors
Kang, G., Srivastava, A., Kim, Y. E., Park, H., Park, C. K., Sohn, T. S., Kim, S., Kang, D. Y., & Kim, K.-M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.11 · Cited by 67
Managing sarcoma: where have we come from and where are we going?
Bleloch, J., Ballim, R. D., Kimani, S., Parkes, J., Panieri, E., Willmer, T., & Prince, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017728927 · Cited by 69
von Mehren, M., George, S., Heinrich, M. C., Schuetze, S. M., Yap, J. T., Yu, J., Abbott, A., Litwin, S., Crowley, J. J., Belinsky, M. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1069 · Cited by 70
Self-citationWaller, C. F. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_1 · Cited by 75
Neville, K. A., Parise, R. A., Thompson, P., Aleksic, A., Egorin, M. J., Balis, F. M., McGuffey, L., McCully, C. L., Berg, S. L., & Blaney, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0155 · Cited by 72
Carney triad: case report and molecular analysis of gastric tumor
Diment, J., Tamborini, E., Casali, P. G., Gronchi, A., Carney, J. A., & Colecchia, M. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.10.003 · Cited by 67
von Bubnoff, N. C. C., Gorantla, S., Kancha, R. K., Lordick, F., Peschel, C., & Duyster, J. (2005) · Leukemia · doi:10.1038/sj.leu.2403887 · Cited by 67
Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
Demetri, G. D. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.018 · Cited by 67
Self-citationCombination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Lee, J.-M., Sarosy, G., Annunziata, C. M., Azad, N. S., Minasian, L. M., Kotz, H. L., Squires, J., Houston, N. D., & Kohn, E. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605514 · Cited by 66
Swick, B. L., Ravdel, L., Fitzpatrick, J. E., & Robinson, W. A. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00613.x · Cited by 66
Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics
McLaughlin, J., Cheng, D., Singer, O., Lukacs, R. U., Radu, C. G., Verma, I. M., & Witte, O. N. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710532105 · Cited by 67
The safety profile of imatinib in CML and GIST: long-term considerations
Thanopoulou, E., & Judson, I. R. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0729-7 · Cited by 66
Cardiac toxicity: old and new issues in anti-cancer drugs
Sereno, M., Brunello, A., Chiappori, A., Barriuso, J., Casado, E., Belda-Iniesta, C., de Castro, J., Feliú, J., & González-Barón, M. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0150-8 · Cited by 71
Metadata
- Authors
- Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D. M., & Joensuu, H.
- Affiliations
- Harvard University (US)
- Oregon Health & Science University (US)
- Fox Chase Cancer Center (US)
- Novartis (Switzerland) (CH)
- University of Helsinki (FI)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08-15
- Volume
- 347
- Issue
- 7
- Pages
- 472-480
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015015957
- Cited by
- 4,389
- References
- 21
- Citations by year
- 2026: 85 · 2025: 91 · 2024: 107 · 2023: 115 · 2022: 117 · 2021: 128 · 2020: 136 · 2019: 119 · 2018: 131 · 2017: 136 · 2016: 160 · 2015: 182 · 2014: 192 · 2013: 210 · 2012: 255
- FWCI
- 167.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- CRC Press eBooks (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Northwest Health Foundation
- Helsingin Yliopisto
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal Tumor Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Keywords
- imatinib mesylate, gastrointestinal stromal tumor, KIT receptor tyrosine kinase, tyrosine kinase inhibitors, antitumor immunity, drug resistance, pharmacokinetics, adverse effects, metastatic cancer, dose comparison
- MeSH terms
- Imatinib Mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzamides, Female, Gastrointestinal Neoplasms, Humans, Male, Middle Aged, Piperazines, Protein-Tyrosine Kinases, Pyrimidines, Remission Induction, Signal Transduction, Survival Analysis, Stromal Cells, Proto-Oncogene Proteins c-kit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.